Abstract: The disclosure in some aspects relates to recombinant adeno-associated viruses having distinct tissue targeting capabilities. In some aspects, the disclosure relates to gene transfer methods using the recombinant adeno-associated viruses. In some aspects, the disclosure relates to isolated AAV capsid proteins and isolated nucleic acids encoding the same.

Abstract: In some aspects the disclosure provides compositions and methods for promoting expression of functional NEU1 protein in a subject. In other aspects, the disclosure provides compositions and methods for treating sialidosis, galactosialidosis, and/or Alzheimer's Disease in a subject having or suspected of having sialidosis, galactosialidosis, and/or Alzheimer's Disease.

Abstract: The invention provides novel zwitterionic monomers and polymers (including copolymers) with pendent phosphonium-based zwitterionic moieties, and compositions and products comprising same, as well as related methods and uses of the compositions, for example, as surfactants, coatings, and interlayer materials, biomedical materials or agents.

Abstract: Methods that include inhibition of ROCK1/2 and other protein kinases to treat Friedreich Ataxia.

Abstract: The present disclosure provides, in some aspects, a humanized immunodeficient mouse model of human fibrosis. A humanized immunodeficient mouse model provided herein may be used, for example, for modeling human fibrosis, predicting human fibrosis, and testing putative fibrosis treatments.

Abstract: The disclosure provides rocaglate acyl sulfamides (Roc ASFs), compositions and kits comprising same, and methods for their use.

Abstract: An impact protecting device includes flocked energy absorbing material (FEAM) impact force absorbing (IFA) segments. Each segment includes a double-sided flock section; a segment cover disposed covering the double-sided flock section and an outer elastic cover enclosing the plurality of FEAM IFA segments including stitching to keep the segments adjacent to adjoining segments but separated. The device further includes overlapped segments to provide extra head protection for the forehead and frontal head areas.

Abstract: Methods for treating or reducing the risk of a cytomegalovirus infection in a subject that include administering one or more of an inhibitor of Deleted in Malignant Brain Tumors 1 (DMBT1), an inhibitor of OR14I1, or an inhibitor of adenylyl cyclases.

Abstract: Absolute blood volume in dialysis patients is a useful patient attribute to know for dialysis treatment, diagnosis, adjustments, etc. In some cases, it is difficult or impossible to directly determine absolute blood volume. Estimating absolute blood volume may be used to overcome the inability to directly determine the absolute blood volume. Estimating absolute blood volume may include obtaining a series of measurements of hemoconcentration of a patient over a time period, and estimating parameters for a physiological model based on the series of measurements. The absolute blood volume of the patient may be determined using the physiological model.

Abstract: A chromogenic assay includes a substrate comprising an array of 5 or more dyes which react with volatile organic compounds, wherein the dyes are chromogenic when reacted with volatile organic chemical biomarkers, wherein the volatile organic chemical biomarkers comprise acids, alcohols, aldehydes, alkenes, amines, antioxidants, aromatic compounds, esters, ethylene, lactones, ketones, organosulfur compounds, sulfides, reactive oxygen species, terpenes, or a combination thereof. A method of detecting volatile organic chemical biomarkers includes contacting the chromogenic assay with a sample or sample headspace, wherein the sample or sample headspace is suspected of containing volatile organic chemical biomarkers, and identifying, based on a colorimetric pattern on the chromogenic assay after contacting, the source of the volatile organic chemical biomarkers. Also included are articles and systems including the chromogenic assay.

Abstract: Aspects of the disclosure relate to a nucleic acid comprising a heterologous nucleic acid insert flanked by interrupted self-complementary sequences, wherein one self-complementary sequence is interrupted by a cross-arm sequence forming two opposing, lengthwise-symmetric stem-loops, and wherein the other of the self-complementary sequences is interrupted by a truncated cross-arm sequence. Methods of delivering the nucleic acid to a cell are also provided.

Abstract: Examples of a negative pressure wound closure system and methods for using such a system are presented. Certain embodiments facilitate closure of the wound by preferentially contracting to provide for movement of the tissue. Certain embodiments can utilize tissue securing portions that aid in securing the system within a wound.

Abstract: Provided herein are compositions comprising nanoparticles, wherein the nanoparticles comprise at least one payload, wherein the nanoparticles further comprise at least one surface bound functional group and method of their use.

Abstract: A polymer nanoparticle includes a polymer having repeating units of formula (I) wherein X, L1, and R1 are as defined herein. Methods of preparing the polymer nanoparticles and compositions comprising the nanoparticles are also disclosed. The polymers nanoparticles described herein are particularly useful for the treatment of bacterial biofilms.

Abstract: Use of high frequency waves, such a millimeter waves, in many circumstances is prevented due to their inability to diffract around common obstacles. Disclosed herein is a system and method for transforming an incident high frequency wave. The system includes meta-atom pairs that define a surface. The meta-atom pairs generate an electro-magnetic response by interacting with an incident wave. This electro-magnetic response can be modulated by applying voltage to the meta-atom pairs. The electro-magnetic response transforms the incident wave into an emitted wave based on its controlled properties. The system and method are able to, by changing the voltage applied, steer the emitted wave a full 360 degrees as wells as transmit it through the surface without significant power loss. Embodiments enable the transmission through or around many obstacles that would normally interfere with high frequency waves.

Abstract: The invention relates to chemically reactive and/or biologically active compounds, reagents and compositions thereof. More particularly, the invention provides novel reagents that are useful in chemical synthesis, functionalization, delivery, probing and/or analytical measurements of small molecule drugs, proteins, antibodies and other biomolecules. The invention provides novel biologically active agents useful as diagnostics or therapeutics, and related composition and methods of uses thereof.

Abstract: The invention generally relates to polymer-based nano-structures. More particularly, the invention relates to novel, surface-functionalized, guest-host polymer nano-assemblies and nano-delivery vehicles useful in diverse fields including drug delivery, diagnostics and specialty materials. The nano-assemblies and nano-delivery vehicles of the invention are afforded via simplify and reliable approaches.

Abstract: Provided herein are compounds of Formulae (I) and (II), and pharmaceutically acceptable salts, solvates, hydrates, polymorphs, co-crystals, tautomers, stereoisomers, isotopically labeled derivatives, and prodrugs thereof. Also provided are methods, uses, and kits involving the disclosed compounds and pharmaceutical compositions thereof for treating and/or preventing a disease (e.g., a metabolic disorder (e.g., obesity, diabetes), a hypoxia related disease (e.g., a proliferative disease, inflammatory disease, neuromuscular disorder, neurodegenerative disorder, hypoxia, ischemia, oxidative stress, or a mitochondrial DNA related disorder), or a disease resulting from rhodoquinone depletion (e.g., a proliferative disease, inflammatory disease, neuromuscular disorder, metabolic disorder, or neurodegenerative disorder)) in a subject.

Abstract: Aspects of the disclosure relate to barcoded chimeric adeno-associated virus (AAV) capsid libraries, chimeric capsids and related recombinant AAVs (rAAVs) identified using the libraries. Specifically, the chimeric AAV capsid libraries comprise a plurality of nucleic adds encoding AAV capsid proteins, wherein each nucleic acid (i) encodes a unique AAV capsid protein having distinct polypeptide regions of greater than six amino acids in length that are derived from at least two different AAV serotypes, and (ii) comprises a unique barcode sequence. Further disclosed are methods of preparing an AAV library and identifying AAV capsids tropic for a target tissue.

Abstract: Described herein are compounds of the formula (I), as well as pharmaceutical compositions comprising such compounds, and methods for using such compounds/pharmaceutical compositions for treating neurodegenerative diseases including Alzheimer's disease, Parkinson's disease, Huntington's disease, and multiple sclerosis (MS).